Loading organizations...
§ Private Profile · Boston, MA, USA
OM1 is a technology company.
OM1 has raised $171.0M across 4 funding rounds.
Key people at OM1.
OM1 has raised $171.0M in total across 4 funding rounds.
OM1 develops a platform that leverages AI-powered real-world data to measure health outcomes, accelerate research, and improve clinical decision-making. The company specializes in aggregating and analyzing large-scale clinical data, applying advanced analytics and artificial intelligence to derive actionable insights across various chronic conditions. Its core offering provides a comprehensive view of patient journeys and treatment effectiveness, bridging the gap between traditional clinical evidence and the dynamic needs of healthcare.
The company was founded in 2015 by Dr. Richard Gliklich, a physician with a longstanding background in health outcomes and data management since 1999. Dr. Gliklich's insight stemmed from the recognized need to bridge the chasm between what healthcare demands and what conventional evidence methodologies can provide. His vision was to build a data and technology solution capable of delivering robust, real-world evidence for better patient care.
OM1’s product serves various stakeholders across the healthcare ecosystem, including life sciences companies, healthcare providers, and academic researchers seeking deeper understanding of disease progression and treatment impact. The company’s long-term vision centers on transforming healthcare by continuously delivering high-quality, real-world evidence that powers more informed medical decisions and fosters innovation in the treatment of chronic diseases.
Key people at OM1.
OM1 is a Boston-based technology company founded in 2015 that builds the OM1 Real-World Data Cloud, a platform combining big clinical data from over 300 million patients, AI, and machine learning to deliver research-grade real-world evidence (RWE) for healthcare stakeholders.[1][2][4][6] It specializes in chronic diseases, personalized medicine, evidence generation, and RWE research, serving pharma, providers, payers, and patients by enabling faster access to precise outcomes data for drug approvals, post-market commitments, trial optimization, and predictive modeling.[1][2][5] Key products include automated data networks, premium datasets, advanced analytics, and precision modeling, with recent growth shown through awards like Frost & Sullivan's 2024 New Product Innovation and 2025 Life Sciences RWE top contender status, plus network expansions adding 500,000 neurology patients in August 2025.[6][7]
OM1 was founded in 2015 in Boston, Massachusetts, emerging as a pioneer in reimagining healthcare measurement through real-world data and AI integration.[2] While specific founders are not detailed in available sources, the company originated from a focus on transforming how outcomes are measured and delivered, starting with the development of the OM1 Real-World Data Cloud to address gaps in clinical data usability.[1][5] Early traction came from building automated data networks and specialty datasets in chronic diseases, evolving into a full-stack platform with billions of data points, AI-driven predictives, and tools for FDA submissions and commercialization support; pivotal moments include recent expansions like the high-quality Rheumatoid Arthritis dataset rating and neurology network growth in 2025.[1][6][7]
OM1 stands out in the RWE space through these key strengths:
OM1 rides the AI-powered RWE and personalized medicine wave, capitalizing on exploding demand for real-world data amid regulatory shifts like FDA's emphasis on RWE for approvals and post-market evidence.[1][6] Timing is ideal as healthcare shifts from siloed datasets to integrated, predictive platforms—OM1's 300+ million patient cloud and cognitive tech address market forces like rising trial costs, payer scrutiny, and precision therapy needs, enabling earlier diagnosis via ML and better provider patterns prediction.[1][4] It influences the ecosystem by setting benchmarks in data quality (e.g., top-rated RA dataset) and innovation, partnering with global pharma like Lilly, fostering scalable networks, and pushing RWE into practice for improved patient outcomes and research efficiency.[6][7]
OM1 is poised for accelerated growth through ongoing network expansions, AI enhancements like digital phenotyping, and deepening pharma collaborations, with trends like regulatory RWE adoption and multimodal data integration (e.g., EMR harmonization, imaging) shaping its path.[6][7] Expect influence to evolve via tools like OM1 Aspen for automated evidence and webinars on AI strategies, potentially capturing more market share in neurology, RA, and beyond as 2025 awards signal momentum. This positions OM1 as a transformative force, directly advancing the healthcare measurement revolution it set out to ignite.[1][5][6]
OM1 has raised $171.0M across 4 funding rounds. Most recently, it raised $85.0M Series D in July 2021.
OM1 has raised $171.0M in total across 4 funding rounds.
OM1's investors include Breyer Capital, D1 Capital Partners, Kaiser Permanente, A Capital, Arbor Ventures, Benchmark, Bessemer Venture Partners, Cisco Investments, Citi Ventures, Felix Capital, General Catalyst, L Catterton Growth.
